Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8831995 | 0.67 | — | — | |
| SCHEMBL2702334 | 0.65 | FDPS (0.50) | LMNAFDPSPDE3AADRB3PDE4D | |
| Phosphoric Acid SCHEMBL28897780 | 0.64 | LMNA (0.37) | LMNAFDPSPDE3AADRB3PDE4D | |
| SCHEMBL28195818 | 0.61 | LMNA (0.35) | LMNAFDPSPDE3AADRB3PDE4D | |
| SCHEMBL11139313 | 0.61 | — | — | |
| Phosphoric Acid SCHEMBL25335734 | 0.58 | — | — | |
| SCHEMBL19668697 | 0.57 | LMNA (0.45) | LMNAFDPSPGK1PGK2 | |
| SCHEMBL15411105 | 0.57 | FDPS (0.48) | LMNAFDPSPDE3AADRB3PDE4D | |
| SCHEMBL6667332 | 0.57 | FDPS (0.48) | LMNAFDPSPDE3AADRB3PDE4D | |
| SCHEMBL7401246 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737816-A1 | INTEGRIN MODULATORS AND METHODS FOR THEIR USE | Billings Pharmaceuticals, Inc. (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005087717-A1 | INTEGRIN MODULATORS AND METHODS FOR THEIR USE | BILLINGS PHARMACEUTICALS INC. (US) | 2005-09-22 | — | — | WO | claimed |
| EP-1003558-B1 | LIPID-POLYAMIDE CONJUGATES AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | CHIRON CORP (US) | 2004-03-17 | — | — | EP | claimed |
| US-6572881-B1 | Delivery of polynucleotides to cells; polylactam | CHIRON CORPORATION | 2003-06-03 | — | — | US | claimed |
| US-6569450-B1 | For facilitating the delivery of polynucleotides to cells | CHIRON CORPORATION | 2003-05-27 | — | — | US | claimed |
| US-6197332-B1 | ACYLATION AND AMIDATION TO FORM POLYAMIDES FOR CONJUGATED LIPIDS | CHIRON CORPORATION | 2001-03-06 | — | — | US | claimed |
| EP-0317968-B1 | Glycerides as charge directors for liquid electrostatic developers | DU PONT (US) | 1994-04-06 | — | — | EP | claimed |
| US-4886726-A | UNIFORM, HIGH QUALITY COPY IMAGES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-12-12 | — | — | US | claimed |
| EP-0317968-A2 | Glycerides as charge directors for liquid electrostatic developers | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-31 | — | — | EP | claimed |
| CN-114085297-A | Cyclo beta-1, 2-glucan and curcumin clathrate compound and preparation method thereof | 江南大学 | 2022-02-25 | — | — | CN | disclosed |
| US-20210198671-A1 | PROTECTED ANTIBODY-DRUG AND APTAMER-DRUG CONJUGATES | KOSAK KENNETH MICHAEL (US) | 2021-07-01 | — | — | US | disclosed |
| CN-108265090-B | Preparation method of antarctic krill oil substitute | 中粮集团有限公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-106893747-B | Preparation method of PLA1 type n-3 polyunsaturated fatty acid phospholipid | 中粮集团有限公司 | 2021-03-05 | — | — | CN | disclosed |
| US-20120149940-A1 | Integrin Modulators and Methods for Their Use | BILLINGS PHARMACEUTICALS, INC. | 2012-06-14 | — | — | US | disclosed |
| EP-0317968-B1 | Glycerides as charge directors for liquid electrostatic developers | DU PONT (US) | 1994-04-06 | — | — | EP | disclosed |
| US-4981957-A | VIRICIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1991-01-01 | — | — | US | disclosed |
| US-4886726-A | UNIFORM, HIGH QUALITY COPY IMAGES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0317968-A2 | Glycerides as charge directors for liquid electrostatic developers | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-31 | — | — | EP | disclosed |
| EP-0169775-B1 | OLIGONUCLEOTIDES, PROCESS FOR THEIR PREPARATION AND THEIR USES AS MEDIATORS IN THE ENHANCEMENT OF THE EFFECTS OF INTERFERONS | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1989-05-24 | — | — | EP | disclosed |
| EP-0169775-A1 | Oligonucleotides, process for their preparation and their uses as mediators in the enhancement of the effects of interferons | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1986-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149940-A1 | Integrin Modulators and Methods for Their Use | ITGA5, ITGB1, ITGB5 | LMNA 2337/4885FDPS 1241/4885PDE3A 799/4885 |
| US-20210198671-A1 | PROTECTED ANTIBODY-DRUG AND APTAMER-DRUG CONJUGATES | ZFR, APP, RBM26 | LMNA 1504/4885FDPS 2741/4885PDE3A 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.